Close Menu

Somalogic

The companies will partner on two clinical studies in dementia that combines Wavi's electroencephalogram-based biomarkers and SomaLogic's blood-based protein biomarkers.

SomaLogic will provide New England Biolabs with protein-binding reagents for use in NEB's nucleic acid amplification and PCR products.

SomaLogic will supply NEB with certain of its SomaMers technology to be incorporated into NEB's products as reversible inhibitors of thermally active DNA polymerases used in PCR.

In particular, the study indicates that the technology's limit of detection is not yet sufficient to detect key low-abundance proteins and that it suffers from reproducibility issues that, while ultimately resolvable, could present significant practical obstacles in a clinical environment.

Anticipating that NGS will become a key clinical tool in coming years, several proteomics firms and researchers are investigating it as a platform for protein biomarker detection assays that use nucleotides as capture agents, hoping to take advantage of the technology's precision and multiplexing ability.

The trials will evaluate biomarker panels for lung, colon, and prostate cancer, and may include a comparison of proteomics-based lung cancer tests from Somalogic and Celera.

The company released results from studies of its six-protein diagnostic panel for lung cancer at this month's AACR meeting and this summer may take part in a 300-patient trial sponsored by the NCI's Early Detection Research Network.

In a study involving 38 mesothelioma patients and 62 asbestos-exposed controls, the 13-protein panel distinguished between the two with a sensitivity and specificity of 92 percent, said one of the researchers.

Life Technologies, Takara Shuzo, SomaLogic, and the University of California are awarded US patents.

Pages

Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.

The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.

One gene regulates hundreds of others to influence facial development, according to New Scientist.

In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.